New hepatitis C diagnoses in Ontario, Canada are associated with the local prescription patterns of a controlled‐release opioid
- 18 March 2020
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 27 (8), 774-780
- https://doi.org/10.1111/jvh.13292
Abstract
Increases in acute hepatitis C virus (HCV) incidence may be a result of the rising prevalence of injection‐drug use and the opioid epidemic. Amongst persons who inject drugs, sharing of needles/syringes is less common and leads to a smaller proportion of incident cases than does sharing of injection drug preparation equipment. In Canada and Europe, hydromorphone controlled‐release has been associated with frequent reuse and sharing of IDPE. Drug excipients within HCR have been shown to preserve virus survival within IDPE. We hypothesized that regional differences in HCV incidence would mirror regional differences in HCR prescribing. We reviewed HCV incidence data across Ontario, Canada for 2016. Opioid prescribing patterns in each Health Unit were reviewed. Multivariable Poisson regression analyses were performed to test the strength of hydromorphone controlled‐release dispensing patterns in explaining HCV incidence compared to all opioids. Less vehicle access, lack of education, lower income, less population density, higher white race/ethnicity, and more opioid substitution therapy recipients remained significant positive predictors of hepatitis C incidence in the Ontario model. Higher hydromorphone controlled‐release dispensing rate was a stronger predictor of HCV incidence than all opioid prescriptions (standardized Risk Ratio=1.17, p<0.0001 vs sRR=1.11, p=0.02). When hydromorphone controlled‐release was excluded from the opioid prescription variable, dispensing patterns of all other opioids no longer remained a significant predictor(sRR=1.042, p=0.34). The observed relationship between HCV incidence and hydromorphone controlled‐release dispensing suggests that the type of opioid prescribed locally may contribute to variations in HCV incidence. These data add support to evidence that hydromorphone controlled‐release use is contributing to HCV spread in Ontario.Keywords
This publication has 20 references indexed in Scilit:
- County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance SystemAnnals of Internal Medicine, 2015
- The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of AddictionAnnual Review of Public Health, 2015
- Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug UsersJAMA Internal Medicine, 2014
- Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay SystemsJournal of Visualized Experiments, 2014
- Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012Clinical Infectious Diseases, 2014
- Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharingDrug and Alcohol Dependence, 2013
- Rethinking Opioid Prescribing to Protect Patient Safety and Public HealthJAMA, 2012
- Injection of drug residue as a potential risk factor for HCV acquisition among Montréal young injection drug usersDrug and Alcohol Dependence, 2012
- Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysisJournal of Viral Hepatitis, 2005